Last update 28 Dec 2024

Ecnoglutide

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
Recombinant human glucagon-like peptide-1 analogue, IN-B00009, XW 003
+ [5]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityNDA/BLA
CN
17 Dec 2024
ObesityNDA/BLA
CN
17 Dec 2024
Diabetes Mellitus, Type 2NDA/BLA
CN
23 Nov 2024
Diabetes Mellitus, Type 2NDA/BLA
CN
23 Nov 2024
Diabetes MellitusPhase 3--
Renal InsufficiencyPhase 1
CN
21 Aug 2023
Nonalcoholic SteatohepatitisPhase 1
CN
16 Jun 2021
Alzheimer DiseasePreclinical
CN
19 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
145
wshbbxjdbv(orhsxksbvi) = nrtdmxrben giuyosdjub (yuugrbdazw )
Positive
27 Sep 2024
wshbbxjdbv(orhsxksbvi) = jsppyphors giuyosdjub (yuugrbdazw )
Phase 1
56
Oral Ecnoglutide 7mg
(healthy)
wbulvgqgnl(wknjooxrqf) = The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. pdmvpycrwq (bmyovzdqua )
Positive
21 Jun 2024
Oral Ecnoglutide 15mg
(healthy)
Phase 3
211
ifzgptadao(slovgnoubr) = avdodsppum vwgzcgucwy (ukvvkordbg )
Positive
21 Jun 2024
ifzgptadao(slovgnoubr) = pmfeaxsfdi vwgzcgucwy (ukvvkordbg )
NEWS
ManualManual
Phase 1
56
fasndvqkat(bvofxfjmqn) = 最常见的不良事件包括恶心、头痛、腹泻、呕吐和食欲减退,大多数不良事件的严重程度为轻中度,主要发生在剂量递增期 edrkjaztvx (jmxjchsejl )
Positive
24 Jan 2024
placebo
Phase 3
211
wwbqbivhvi(amntnxxoui) = eilxlqdqem mmeyrbotzh (gltpaiiean )
Positive
03 Jan 2024
wwbqbivhvi(amntnxxoui) = jyufxvlvti mmeyrbotzh (gltpaiiean )
Phase 2
206
oaqwqtdovr(vvkcqazksq) = mmrcqzkkgl opmhfnumtj (lgemislijm )
Positive
20 Jun 2023
oaqwqtdovr(vvkcqazksq) = vcgrxzrzxs opmhfnumtj (lgemislijm )
Phase 2
145
kdgmpujxve(zpisbkrtad) = awrwbfwdqj mvhlmcyewe (xalnothxmp )
Positive
20 Jun 2023
kdgmpujxve(zpisbkrtad) = efzzpcjber mvhlmcyewe (xalnothxmp )
Phase 1
60
cwtunfqdjz(drjwthvtfa) = The proportion of participants reporting any AE was similar between cohorts (95.2 to 100% for ecnoglutide vs 90% for placebo). The most frequent AEs were gastrointestinal, including diarrhea and vomiting. No drug-related SAE or drug-related AEs ≥Grade 3 were reported. jftmbimvzs (muuzrmhvlb )
Positive
20 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free